Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.
Completed · Phase 2
Conditions studied: Sarcoma, Kaposi, HIV Infections
In brief
To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.
Key facts
- Study ID
- NCT00002167
- Run by
- Clinical Solutions
- People needed
- 78
- Last updated by the study team
- 2005-06-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have:
- Documentation of at least one biopsy-confirmed KS lesion.
- A minimum of 4 and no more than 36 KS lesions.
- All eligible lesions must be bidimensionally measurable, treatable by surface (non-contact) light illumination, and <= 40 mm in diameter of the longest bidimensional axis.
- ACTG disease state T(0) L(0) or (1) S(0) or (1).
- Life expectancy greater than 6 months.
You may not qualify if…
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- Active opportunistic infection or condition except thrush or herpes simplex virus infections.
- Advanced KS tumor stages including the presence of tumor associated edema or ulceration, extensive oral KS, or KS in other non-nodal viscera.
- Hematopoietic dysfunction.
- Coagulation dysfunction.
- Hepatic dysfunction.
- Renal dysfunction.
- Cardiovascular dysfunction - Presence of significant coronary artery disease requiring current treatment or myocardial infarction.
- Pulmonary dysfunction.
- Sepsis.
- Known disorder of lipoprotein metabolism or clearance.
- Patients with the following prior conditions are excluded:
- History of allergic or hypersensitivity reactions to light, egg proteins or egg yolks, history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.
- Excluded within 7 days of therapy:
- Hematopoietic dysfunction.
- Coagulation dysfunction.
- Hepatic dysfunction.
- Renal dysfunction.
- Excluded within 3 months of therapy:
- Pulmonary dysfunction.
- Excluded within 6 months of therapy:
- Myocardial infarction.
- Prior Medication:
- Excluded:
Where it is running
- Univ of Southern California / Los Angeles — Los Angeles, California, United States
- Cedars Sinai Med Ctr — Los Angeles, California, United States
- Univ of California / San Francisco / Dermatology — San Francisco, California, United States
- Health One - Rocky Mountain Cancer Ctr — Denver, Colorado, United States
- Buffalo Gen Hosp / PDT Ctr — Buffalo, New York, United States
- Thompson Cancer Survival Ctr — Knoxville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.